Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30940022 | 0.98 | ESR1 (0.60) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL22803724 | 0.87 | ESR1 (0.63) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL4347943 | 0.86 | NPC1 (0.69) | MAOANOTUMNPC1MAPTRAB9A | |
| SCHEMBL31668714 | 0.86 | ESR1 (0.61) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL29978546 | 0.84 | ESR1 (0.60) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL30005991 | 0.84 | MAOA (0.64) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL13135962 | 0.84 | MAOA (0.64) | ESR1MAOAKDM4EALDH1A1HPGD | |
| SCHEMBL5490235 | 0.84 | ESR1 (0.60) | ESR1MAOAKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL12492073 | 0.84 | NPC1 (0.68) | MAOANOTUMNPC1MAPTRAB9A | |
| SCHEMBL27375907 | 0.83 | NPC1 (0.61) | ESR1MAOANOTUMNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3454862-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2814486-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | KINETA FOUR LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| CN-104507473-A | Antiviral drug for treatment of arenavirus infection | SIGA TECHNOLOGIES INC | 2015-04-08 | — | — | CN | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2814486-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013123215-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | EIF2AK2, ZC3HAV1, SARS1 | ESR1 4692/4885MAOA 2632/4885KDM4E 4051/4885 |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | ESR1 4692/4885MAOA 2632/4885KDM4E 4051/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ESR1 233/4885MAOA 3894/4885KDM4E 1930/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ESR1 233/4885MAOA 3894/4885KDM4E 1930/4885 |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | ESR1 4692/4885MAOA 2632/4885KDM4E 4051/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ESR1 233/4885MAOA 3894/4885KDM4E 1930/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ESR1 233/4885MAOA 3894/4885KDM4E 1930/4885 |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ESR1 233/4885MAOA 3894/4885KDM4E 1930/4885 |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | ESR1 35/4885MAOA 2407/4885KDM4E 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.